On September 2, China's innovative biopharmaceutical company Frontier Biopharmaceutical (Nanjing) Co., Ltd. launched the world's first long-acting HIV-1 fusion inhibitor - Aiboweitai (Akoning®) on the global launch conference in Nanjing Held.
Akonin® is a human immunodeficiency virus (HIV-1) fusion inhibitor that is used in combination with other antiretroviral drugs to treat HIV-1 virus replication through treatment with a variety of other antiretroviral drugs. HIV-1 infected person.
Akonin® is the world's first long-acting HIV-1 fusion inhibitor, China's first original anti-Ai Ai drug, which has been independently developed by leading-edge organisms and has global intellectual property rights. Akonin® has a novel molecular mechanism of action, is effective against the popular HIV-1 virus and drug-resistant virus, and has unique advantages such as low frequency of administration (once a week), high drug resistance barrier and high safety.
➦ AIDS prevention and control faces serious challenges
AIDS is a major infectious disease in the public health field, mainly through sexual transmission. The HIV virus mainly attacks the human immune system, and takes the most important CD4T lymphocytes in the human immune system as the first target. It damages immune cells in a large area, causes the human body to lose its immune function to the outside world, and is susceptible to various diseases, including malignant tumors. It has led to a higher mortality rate of AIDS.
From 2010 to 2017, the number of AIDS cases and deaths in China has generally been on the rise. According to the National Health and Health Commission's statistical bulletin on the development of China's health and health undertakings, the number of AIDS cases in 2017 was 57,194, and the number of deaths was 15,251, ranking first in the national Class A and B infectious diseases. The number of newly infected people exceeded 100,000 in the year. As of July 31, 2017, 728,270 people living with HIV/AIDS were reported nationwide.
For a long time, China's AIDS treatment drugs are imported drugs or generic drugs, and there is no independent research and development of anti-Ai Xin drugs. The demand for clinical treatment against Ai Xin drugs has grown rapidly, so that Chinese patients who use self-developed anti-Ai Xin drugs and good drugs have always been medicines. The dream that the world strives to achieve.
“Akoning® is the first anti-Aiyi drug in China, and it is also the world's first long-acting HIV-1 fusion inhibitor listed in China. It represents a new level of anti-AIDS drug research and development in China. Akonin® has a better therapeutic effect on drug-resistant patients with treatment failure, and the side effects are smaller than other types of drugs, so a new treatment is added for patients with treatment failure and patients who cannot be tolerated due to side effects of other drugs. The choice will also enable better medical treatment for AIDS patients in our country. Due to the new mechanism of action of Aikeneng®, it is expected that early intervention and prevention will be carried out for some exposed populations. Professor Li Taisheng, the chairman of the Infectious Diseases Branch of the Chinese Medical Association, said Professor Li Taisheng, director of the Infectious Diseases Department of the Union Hospital.
➦ Long-acting drugs have created a new era of AIDS treatment
At present, there are more than 30 anti-AIDS drugs and multiple compound preparations listed in the world, and there is only one long-acting injection. Some patients who use many drugs for a long time will inevitably develop drug resistance, which not only endangers the life and health of patients, but also may cause the spread of drug-resistant viruses.
“The success of Aikeneng® is the result of the creation of major new drugs, the crystallization of the wisdom of researchers, and a model for clinical cooperation between Chinese pharmaceutical R&D and medicine. After the listing, Aikeneng® has filled several gaps in antiviral drugs in China. : First, it is the world's first long-acting HIV fusion inhibitor, opening the era of long-acting anti-AIDS drugs in China; secondly, the new mechanism of action of Akonin® is effective against known drug-resistant viruses, and existing drug mechanisms Complementary, can save the lives of patients; again, as a peptide drug for injection, Akonin® has small side effects, high safety, and is not affected by oral and gastrointestinal functions, and can meet some urgent clinical drug needs. . Professor Eason, director of the Aikeneng® Clinical Trial, and director of the Beijing You'an Hospital Infection Center affiliated to Capital Medical University, said.
➦ Fill in the anti-Ai New Drug gap
The results of the Akoning® clinical trial showed that the combination of Akonin® and antiretroviral drugs was comparable or superior to the standard drug recommended by the World Health Organization, and the renal safety was significantly better than the control group. It provides a more optimal treatment plan for AIDS antiviral treatment, and more drug selection, providing new treatment options and new hopes for patients with drug resistance, surgery and hospitalization at home and abroad.
Aikeneng® successfully developed and listed, not only filled the gap in China's anti-AIDS research and development, but also improved the overall level of China's independent research and development, and created a new situation of long-acting anti-AIDS drug treatment, leading the international treatment trend, reflecting the original Chinese strength.
This article is reproduced from：https://news.pharmacodia.com/news/html/info/info-detail.html?id=29809
